Presentation is loading. Please wait.

Presentation is loading. Please wait.

Epidemiological and Pharmacoeconomic Aspects of Alzheimer‘s Disease and Dementia.

Similar presentations


Presentation on theme: "Epidemiological and Pharmacoeconomic Aspects of Alzheimer‘s Disease and Dementia."— Presentation transcript:

1 Epidemiological and Pharmacoeconomic Aspects of Alzheimer‘s Disease and Dementia

2 United Nations Economic and Social Council 2000 Age Distribution of the World Population Age malefemale 19502050 100 80 60 40 20 0 malefemale

3 World Population Prospects, The 2002 Revision Average Annual Growth Rates of the World Population Percentage (%) 4 3 2 1 0 0 – 14 3.39 15 – 59 60+80+ Age 2.29 0.72 -0.04 Average Annual Growth (2000-2050 Medium variant)

4 Prevalence of Dementia Prevalence Rate (%) 25 20 15 10 5 0 65–69 23.6 70–7475–7980–84 Age 11.1 5.6 World (estimated) 85+ 2.8 1.4 Jorm et al., Acta Psychiatrica Scandinavica 1987

5 Types of Dementia EuropeNorth America Asia Fratiglioni et al., Drugs Aging 1999 Alzheimer‘s disease Vascular dementia Other 61.4%27.6% 11.0% 74.5% 10.0% 15.5% 46.5% 38.1% 15.4%

6 Caregiver Costs Increase with Increasing Severity of Dementia (Germany) Annual Costs (€) 16,000 12,000 8,000 4,000 Community Setting Institutional Setting Hallauer, 2002 MMSE 26 – 21 MMSE 20 – 15 MMSE 14 – 10 MMSE <10

7 Diagnosis and Treatment Statistics of Alzheimer‘s Disease On average AD patients live 8 to 10 years after diagnosis AD can last for up to 20 years treated with modern therapy < 6% diagnosed (most in later stages) 52% treated 9% patients with AD in Europe ~ 8 Mio. Cognos Report, 2002

8 Potential Reduction in Caregiver Time Figure adapted according to references Potential to Reduce Caregiver Time Increases with Severity of the Disease 30 mildmoderatesevereAD MMSE Score 20100 7h/month (Donepezil) 1 12h/month (Galantamine) 2 52h/month (Memantine) 3 1 Dement Geriatr Cogn Disord 2003; Erratum 2003 2 Chemical Business News Base 2001 3 Wimo et al., Pharmacoeconomics 2003

9 Specific Aspects of Moderate to Severe Alzheimer’s Diseases Caregiver burden and cost of illness is high in patients with moderate to severe AD A treatment which is efficacious in these stages is expected to reduce caregiver and societal cost Memantine treatment has been shown to reduce caregiver and societal costs (Wimo et al., 2003)


Download ppt "Epidemiological and Pharmacoeconomic Aspects of Alzheimer‘s Disease and Dementia."

Similar presentations


Ads by Google